VoxCell BioInnovation

2:00 PM - 2:15 PM (PDT), Monday, June 13, 2022
VoxCell BioInnovation is creating fully vascularized, human-like cancer tissue models by combining a custom 3D bioprinter, advanced vascularization software, and proprietary bioinks. When applied to preclinical drug testing, these tissue models offer significant benefits over currently used platforms due to their 3D vascularized structure, mimicking an artificial biopsy sample. VoxCell aims to accelerate the development of life-saving anti-cancer drugs by providing tissue models that can identify inviable candidates earlier in the drug-development pipeline. Whether it is pharmaceutical companies testing new drugs in the lab, or medical professionals determining which therapy is best for their patients, VoxCell is changing the way we think about in vitro tissue models through 3D bioprinting.
Company Type:
Privately Funded Company
Company HQ State:
British Columbia
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Human-like Tissue Models
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided